David Collier

Dr David Collier is a Clinical Director and Research Fellow at the William Harvey Research Institute, part of Queen Mary University of London's Faculty of Medicine and Dentistry. He specializes in clinical research methodologies, particularly in hypertension management, renal denervation, and patient recruitment strategies. His work focuses on optimizing clinical trial design and improving patient engagement through innovative approaches like multimedia interventions.

Collier co-leads an MRC-funded START program exploring recruitment methods for clinical trials and contributed to groundbreaking studies such as the Symplicity 2 trial on renal denervation. He pioneered the UK's first renal denervation procedure in 2010 and has developed health services interventions like the HiLo trial to address hypertension disparities. His research also extends to cardiovascular outcomes from landmark trials like ASCOT, influencing NICE guidelines for hypertension treatment.

His recent work includes trials assessing antihypertensive therapies (e.g., amlodipine optimization in the PERSONAL-CovidBP trial) and evaluating novel treatments for conditions like PIMS-TS. Collier actively collaborates with international teams, contributing to high-impact publications in The Lancet and other journals. He emphasizes patient-centered approaches, ensuring trial information is accessible through creative formats like Trials Connect events.

• Key Affiliations: NIHR Cardiovascular Biomedical Research Unit, ResRecMG (NIHR PCRN), and Barts Health NHS Trust.
• Major Projects: START grant, Symplicity renal denervation studies, and the ASCOT trial.
• Labs/Teams: Clinical Pharmacology and Precision Medicine group at the William Harvey Research Institute.